

Electronic Acknowledgement Receipt

| | |
|---|---|
| EFS ID: | 5889009 |
| Application Number: | 10524963 |
| International Application Number: | |
| Confirmation Number: | 3567 |
| Title of Invention: | N-(3-Methoxy-5-methylpyrazin-2-yl)-2-(4'-1,3,4-oxadiazol-2-yl-phenyl) pyridine-3- sulphonamide as an anticancer agent |
| First Named Inventor/Applicant Name: | David William Tonge |
| Customer Number: | 44992 |
| Filer: | Jacob G. Weintraub |
| Filer Authorized By: | |
| Attorney Docket Number: | 100815-1P US |
| Receipt Date: | 14-AUG-2009 |
| Filing Date: | 18-FEB-2005 |
| Time Stamp: | 12:26:36 |
| Application Type: | U.S. National Stage under 35 USC 371 |

Payment information:

| | |
|--|-----------------|
| Submitted with Payment | yes |
| Payment Type | Deposit Account |
| Payment was successfully received in RAM | \$ 180 |
| RAM confirmation Number | 7868 |
| Deposit Account | 503231 |
| Authorized User | |

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

| Document Number | Document Description | File Name | File Size(Bytes)/ Message Digest | Multi Part /.zip | Pages (if appl.) |
|-----------------|-------------------------------|--|---|------------------|------------------|
| 1 | Miscellaneous Incoming Letter | IDSreferences.pdf | 52353 | no | 1 |
| | | | f15ebdbbf43d21138b7f9bdf6c3456c9175d4 | | |
| Warnings: | | | | | |
| Information: | | | | | |
| 2 | Foreign Reference | WO1996040681.pdf | 5637755 | no | 109 |
| | | | c1e11052b0ac3f515cd8f27a1ba19458a1ccdo77 | | |
| Warnings: | | | | | |
| Information: | | | | | |
| 3 | Foreign Reference | WO2001044239.pdf | 10694791 | no | 295 |
| | | | 2188bdf4d0b7d41cc78cc7D2d8b13acd18d5a4c2c | | |
| Warnings: | | | | | |
| Information: | | | | | |
| 4 | Foreign Reference | WO2002049630.pdf | 863748 | no | 17 |
| | | | e1142df188eca7809c473db13c3d7cc2a055d83b | | |
| Warnings: | | | | | |
| Information: | | | | | |
| 5 | Foreign Reference | WO2001060370Japanese.pdf | 1168916 | no | 27 |
| | | | 38139c7b201f3d44cc36877f98bd515ea71adecl | | |
| Warnings: | | | | | |
| Information: | | | | | |
| 6 | NPL Documents | EndothelinreceptorAntagonist 1.pdf | 50213 | no | 1 |
| | | | 26442a29a7c4f6f8bda7589a1e1df1b4ad7d1e99 | | |
| Warnings: | | | | | |
| Information: | | | | | |
| 7 | NPL Documents | Theroleofendothelin1andendothelin1.pdf | 324726 | no | 4 |
| | | | 6482cd67d2217962457ab678c3e3acc7c7d64 | | |
| Warnings: | | | | | |
| Information: | | | | | |
| 8 | NPL Documents | ABT627anendothelinETreceptorselective1.pdf | 718919 | no | 7 |
| | | | d218d6e1035c2193c7a39965d25d11e75e077 | | |
| Warnings: | | | | | |
| Information: | | | | | |

| | | | | | |
|--|--|---|---|------------|----|
| 9 | NPL Documents | DatabaseWPISetionChWeek200163.pdf | 97747 67651598d299345f8fbae3256038435b5f5e0955 | no | 2 |
| Warnings: | | | | | |
| Information: | | | | | |
| 10 | Miscellaneous Incoming Letter | 100815Declaration.pdf | 113901 29c2084e7b48b4bcbcd388827c4f8949551e6fe | no | 3 |
| Warnings: | | | | | |
| Information: | | | | | |
| 11 | Miscellaneous Incoming Letter | 100815Postcard.pdf | 17404 1d30b6c1acc566398b3c708d787b4b67c7fbc4b6 | no | 1 |
| Warnings: | | | | | |
| Information: | | | | | |
| 12 | Information Disclosure Statement (IDS) Filed (5B/08) | IDS2.pdf | 926688 03a1338221d454dd7b662818c401dbb701e252b | no | 4 |
| Warnings: | | | | | |
| Information: | | | | | |
| A U.S. Patent Number Citation or a U.S. Publication Number Citation is required in the Information Disclosure Statement (IDS) form for autoloading of data into USPTO systems. You may remove the form to add the required data in order to correct the Informational Message if you are citing U.S. References. If you chose not to include U.S. References, the image of the form will be processed and be made available within the Image File Wrapper (IFW) system. However, no data will be extracted from this form. Any additional data such as Foreign Patent Documents or Non Patent Literature will be manually reviewed and keyed into USPTO systems. | | | | | |
| 13 | NPL Documents | SafetyandEfficacyoftheSpecific Endothelin.pdf | 1023750 b3c4d152880f95c11f90666f5e4478a976731 | no | 12 |
| Warnings: | | | | | |
| Information: | | | | | |
| 14 | NPL Documents | SpecificEndothelin-AReceptorAntagonism.pdf | 93104 6d7aa6e21c25b3b6cafc49c1d0092f25614e75 | no | 3 |
| Warnings: | | | | | |
| Information: | | | | | |
| 15 | NPL Documents | Newendothelin-Areceptorantagonistprolongssurvival.pdf | 51130 e6ab0b61d16c1b5a5e5a33381b7d2a55a2a | no | 1 |
| Warnings: | | | | | |
| Information: | | | | | |
| 16 | | 100815AmendmentandResponse.pdf | 68912 1c4133ed7a877f9474464262a7a6c0a30fd90 | yes | 11 |
| Multipart Description/PDF files in .zip description | | | | | |
| | Document Description | | Start | End | |

| | | | |
|--|---|---|----|
| | Amendment/Req. Reconsideration-After Non-Final Reject | 1 | 1 |
| | Claims | 2 | 3 |
| | Applicant Arguments/Remarks Made in an Amendment | 4 | 11 |

Warnings:

Information:

| | | | | | |
|----|-------------------------|--------------|---------------------------------------|----|---|
| 17 | Fee Worksheet (PTO-875) | fee-info.pdf | 30609 | no | 2 |
| | | | b67c83d2ec9500e71f54da7ee0855bba2cf11 | | |

Warnings:

Information:

| | |
|------------------------------|----------|
| Total Files Size (in bytes): | 21934666 |
|------------------------------|----------|

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.